Purpose: Patients undergoing breast augmentation are treated with multiple combinations of medications for pain control including ketorolac, liposomal bupivacaine, bupivacaine, and intravenous and oral narcotics. There is no current consensus on the optimal combination; therefore, all are used at the discretion of the surgeon. Methods: This was a single-center, retrospective study. The total number of patients included was 132. Comparisons were made between 4 groups: bupivacaine only (B); bupivacaine and liposomal bupivacaine (BL); bupivacaine and liposomal bupivacaine plus intraoperative ketorolac (BLKi); and bupivacaine and liposomal bupivacaine plus postoperative ketorolac (BLKp). Average pain scores immediately postoperative and before discharge were recorded and correlated to percentage of patients who received narcotic in the post-anesthesia care unit (PACU). Additional end points noted were side effects including nausea and time spent in PACU postoperatively. Results: Those receiving intraoperative ketorolac had the lowest pain on discharge (P < 0.0001) and the lowest percentage of patients receiving narcotics (P = 0.009) out of all 4 groups. There was no significant difference between the 4 groups in terms of time spent in PACU, pain immediately after the procedure, or amount of antiemetic given. No bleeding complications were noted for those who did or did not receive ketorolac. Conclusions: When given options for pain control in breast augmentation, intraoperative ketorolac should be considered, because its inclusion was significant in decreasing use of narcotics and pain upon discharge. Addition of other costly drugs such as liposomal bupivacaine may not provide additional benefit in the immediate postoperative setting for procedures with a short recovery period such as breast augmentation.
O ver the past 4 decades, there have been an increasing number of outpatient procedures because of advances in anesthetic and surgical techniques and escalating healthcare costs. Improvement in anesthesia enabled patients to regain consciousness more quickly with fewer after effects and better analgesics for relief of pain.
1 Discharge of patients undergoing outpatient procedures often depends on recovery from anesthesia. Factors that will delay discharge include nausea, vomiting, and unrelieved pain. There are significant consequences of inadequate perioperative pain that include a delay in recovery, a delayed return to normal daily living, and reduced patient satisfaction. 2 Traditional systemic methods of pain control include opioids; however, the adverse outcomes associated with opioids continue to be a major problem in outpatient anesthesia. Potential side effects include altered mental status, narcotic dependence, nausea, emesis, impairment of bowel function, constipation, and respiratory depression. 3 Multimodal analgesics, where local and intravenous analgesics are combined, is a preferred over monotherapies because of lower pain scores, reduced opioid usage, and opioid-related adverse effects.
Breast augmentation was the most common cosmetic surgical procedure (286,000) as per American Society of Plastic Surgeons 2014 Plastic Surgery Statistics Report. Our goal is to provide adequate postoperative analgesia after outpatient breast augmentation while meeting the criteria for discharge. We will evaluate the efficacy of multimodal therapy comparing 4 different techniques: bupivacaine only (B); bupivacaine and liposomal bupivacaine (BL); bupivacaine and liposomal bupivacaine plus intraoperative ketorolac (BLKi); and bupivacaine and liposomal bupivacaine plus postoperative ketorolac (BLKp). We hypothesize that intraoperative use of ketorolac will produce prolonged analgesia, decrease postoperative supplemental narcotic use, and facilitate discharge from post-anesthesia care unit (PACU). We also hypothesize that intraoperative use of liposomal bupivacaine will produce prolonged analgesia in PACU.
MATERIALS AND METHODS

Study Population
This was a single-center, retrospective study that analyzed patients who underwent elective outpatient surgery for breast augmentation. All patients were female and 18 years or older. Patients that underwent surgery for this procedure over a 7-year period were included (2009) (2010) (2011) (2012) (2013) (2014) (2015) . Those who did not receive a combination of bupivacaine and liposomal bupivacaine with or without ketorolac were excluded. Two surgeons performed all operations with similar techniques. Data were collected via a database located at the outpatient surgery center where the procedures were performed. This database held all scanned medical records pertaining to the perioperative care of the patient. The study was approved by the Biomedical Institutional Review Board of Tulane University New Orleans with waiver of consent.
Data Collection
For the purpose of this study, information was collected regarding type of analgesia used intravenously or intramuscularly by anesthesia and subcutaneously by the surgeon intraoperatively. These data were combined with the medications given intravenously and by mouth in the PACU. Timing of the narcotics given postoperatively was also analyzed.
Comparisons were made between 4 groups: bupivacaine only (B); bupivacaine and liposomal bupivacaine (BL); bupivacaine and liposomal bupivacaine plus intraoperative ketorolac (BLKi); and bupivacaine and liposomal bupivacaine plus postoperative ketorolac (BLKp). Outcomes of interest were number of patients that required narcotics in the PACU, amount of narcotic received postoperatively, amount of antiemetic required postoperatively, pain scores upon arrival to PACU, pain scores upon discharge, time in PACU, and complications. The generic unidimensional numeric rating scale was used with "no pain" represented by a score of 0 and "worst imaginable pain" represented by a score of 10. Patient age, body mass index (BMI), and weight were also assessed. All complications after surgery were recorded to determine the rate of hematoma formation within each set of patients.
Initial query of the database of all patients undergoing breast augmentation during appropriate time period identified 132 patients. Division based on combination of analgesic resulted in the following: bupivacaine only (N = 59); bupivacaine and liposomal bupivacaine (N = 26); bupivacaine and liposomal bupivacaine plus intraoperative ketorolac (N = 34); and liposomal bupivacaine and bupivacaine plus postoperative ketorolac (N = 13). Patients were excluded if they had a subglandular augmentation. All remaining patients included in the study received a submuscular augmentation.
Technique
Primary breast augmentation was performed in all patients in the subpectoral plane. Patients were first seen and marked preoperatively. After appropriate induction of anesthesia, skin prepping, and sterile draping, the operation was initiated with injection of local anesthetic into the incision and as an intercostal nerve block, specific to each group as detailed below. An incision was then made at the inframammary fold or periareolar. Dissection was performed such that a subpectoral plane was created using a dual plane technique with complete division of pectoralis origins along the inferior border. Once adequate hemostasis was achieved, injection of local anesthetic into the breast pocket was performed. After implant selection, pocket was irrigated, and permanent saline or silicone implants were placed. No drains were used.
The mean implant volume for the study population was 363 cc with a range of 175 to 550 cc. There was no difference in the mean volume of implant placed between the groups. All implants were round and smooth. Out of 132 patients, 68 (51.5%) had saline implants and 64 (48.5%) had silicone implants. Inframammary incisions were used in 100 (75.8%) out of 132 patients, and periareolar incisions were placed in 32 (24.2%) out of 132 patients.
The injection of local anesthetic for each group was as follows: Patients in the B group ( Fig. 1) were given a mean of 40 mL of bupivacaine with 0.25% epinephrine per patient, and this was injected into 3 areas: (1) into the marked incision before incision, (2) intercostal nerve block before incision, and (3) into the breast pocket after dissection.
Patients in the BL group (Fig. 2) were given a mixture of 20 mL of bupivacaine, 20 mL of liposomal bupivacaine with 0.25% epinephrine, and 20 mL of 0.9% normal saline, and this was injected into 3 areas: (1) into the marked incision before incision, (2) intercostal nerve block before incision, and (3) into the breast pocket after dissection.
Patients in the BLKi group ( Fig. 3) were given a mixture of 20 mL of bupivacaine, 20 mL of liposomal bupivacaine with 0.25% epinephrine, and 20 mL of 0.9% normal saline, and this was injected into 3 areas: (1) into the marked incision before incision, (2) intercostal nerve block before incision, and (3) into the breast pocket after dissection. In addition, ketorolac 30 mg intravenous (IV) and 30 mg intramuscular (IM) were given postincisionally but before the end of procedure.
Patients in the BLKp group (Fig. 4) were given a mixture of 20 mL of bupivacaine, 20 mL of liposomal bupivacaine with 0.25% epinephrine, and 20 mL of 0.9% normal saline, and this was injected into 3 areas: (1) into the marked incision before incision, (2) intercostal nerve block before incision, and (3) into the breast pocket after dissection. In addition, ketorolac 30 mg IV and 30 mg IM were given at the end of procedure.
It should be noted that the use of liposomal bupivacaine as a regional nerve block is off-label and has not been approved by the Food and Drug Administration.
Statistical Analysis
For the continuous measures, data were analyzed using analysis of variance methods. When assumptions of normality were not met, results were verified by analysis with the Kruskal-Wallis test. For categorical measures, differences in frequencies were assessed using Pearson χ 2 test. Subhypotheses were assessed using Bonferroniadjusted P values. FIGURE 1. Patients in the B group were given a mean of 40 mL of bupivacaine with 0.25% epinephrine per patient, and this was injected into 3 areas: (1) into the marked incision before incision, (2) intercostal nerve block before incision, and (3) into the breast pocket after dissection. FIGURE 2. Patients in the BL group were given a mixture of 20 mL of bupivacaine, 20 mL of liposomal bupivacaine with 0.25% epinephrine, and 20 mL of 0.9% normal saline, and this was injected into 3 areas: (1) into the marked incision before incision, (2) intercostal nerve block before incision, and (3) into the breast pocket after dissection.
RESULTS
A total of 132 patients were analyzed in this study and fell into 1 of 4 groups: group B (n = 59), group BL (n = 26), group BLKi (n = 34), and group BLKp (n = 13). There were no significant differences in age or BMI across the groups, and all breast augmentations took place in the same surgical center. Procedures were all performed by 1 of 2 surgeons. Patients in group BLKi had lower pain scores upon discharge at 1.15 (P < 0.0001). Additionally, the smallest number of patients requiring narcotics in PACU was also found in the BLKi group at 29.4% (10 out of 34 patients; P = 0.0094). There was no significant difference between the groups when comparing time in PACU, pain immediately postoperative, number of patients who received antiemetics postoperatively and time in the PACU for patients before they needed pain medications (Table 1) .
DISCUSSION
Breast augmentation has steadily increased in popularity, and parallel to it, the need to optimize postoperative pain control, mitigate cost, and decrease adverse side effects. 4 Placement of the implant into the retromuscular pocket has also increased pain associated with the procedure because of the partial detachment of the sternal and costal origins of the pectoralis major muscle. In our study, we have aimed to demonstrate the best combination of drugs for optimal pain control in this patient population.
Studies show that pain is triggered by sensitization of neurons in the pain pathway. This sensitization can be either central or peripheral. 5 During tissue injury such as surgery, cytokine and prostaglandins are produced. This increases inflammation and, therefore, increases excitability of central neurons in the spinal cord, giving the sensation of pain. 6 During surgery, massive stimulation occurs of peripheral afferent fibers. 7, 8 Other studies also show that C-fibers are activated by brief noxious stimulation, and this may alter central neural function by prolonging their alteration. 9, 10 General anesthesia attenuates this stimulation, but does not prevent it. 8 Traditional analgesic regimens have involved narcotics both intravenously or orally; however, systemic opioid use alone is insufficient to block nociceptive neurons and prevent central sensitization. 10, 11 In addition, there are side effects such as postoperative nausea and vomiting. The spare use of opioids can decrease this effect as well as sedation, disorientation, 10,12 respiratory depression, urinary retention, ileus, [13] [14] [15] headache, constipation, sleep disturbance, and altered mental status, as well as tolerance and abuse that often occur. To reduce use, other modes of analgesia such as nonsteroidal antiinflammatory drugs (NSAIDs) and local anesthetics are advised.
Local anesthetics have the ability to limit central sensitization by limiting impulses to afferent fibers and diminishing spinal cord stimulation and pain processing. 8, 16 This can contribute to a significant painfree period postoperatively. Bupivacaine has a half-life of 2.7 hours, and this duration is prolonged when combined with epinephrine. 12 It is also comparatively inexpensive and can be used to obtain this painfree period. 10, 17 An alternative that is even longer acting is liposomal bupivacaine. This liposomal formulation is administered intraoperatively and releases bupivacaine for up to 96 hours. This has been demonstrated in other studies as an advantageous addition to multimodal analgesia. [18] [19] [20] [21] [22] Nonsteroidal anti-inflammatory drugs have the ability to work both centrally and peripherally. The local inflammatory response from injury is reduced, attenuating peripheral sensitization, which also decreases spinal nociceptive processing. 10 Centrally, they prevent spinal prostanoid synthesis. By reducing both peripheral and central sensitization, pain is reduced in the postoperative period, requiring fewer additional analgesics including decreased total dose of opioids even after major surgery. 8, 16, 23 Nonsteroidal antiinflammatory drugs are likely to be inadequate when used alone. [23] [24] [25] Other studies have demonstrated that a combination of NSAIDs such as ketorolac with other modalities including local anesthetics is safe and superior than the use of each product alone. 8, [23] [24] [25] One study comparing intravenous ketorolac versus placebo for pain control after surgery found that NSAIDs combined with opioids resulted in not only less opioid consumption and better analgesia but also decreased postoperative nausea, vomiting, and sedation. [26] [27] [28] This gives NSAIDs an advantage over opioids in the perioperative period. 10 Ketorolac has even been shown to provide similar analgesic effect to morphine. 29, 30 For mild to moderate postoperative pain, NSAIDS should be the drug of choice. 3, 13 Multimodal analgesia has become the standard in clinical practice in recent decades in attempts to prevent peripheral and central stimulation and control postoperative pain. 26, [31] [32] [33] This approach utilizes combinations of analgesic drugs to optimize pain relief. Drugs with different mechanisms of action can be used to target distinct FIGURE 3. Patients in the BLKi group were given a mixture of 20 mL of bupivacaine, 20 mL of liposomal bupivacaine with 0.25% epinephrine, and 20 mL of 0.9% normal saline, and this was injected into 3 areas: (1) into the marked incision before incision, (2) intercostal nerve block before incision, and (3) into the breast pocket after dissection. In addition, ketorolac 30 mg IV and 30 mg IM were given postincisionally but before the end of procedure.
FIGURE 4.
Patients in the BLKp group were given a mixture of 20 mL of bupivacaine, 20 mL of liposomal bupivacaine with 0.25% epinephrine, and 20 mL of 0.9% normal saline, and this was injected into 3 areas: (1) into the marked incision before incision, (2) intercostal nerve block before incision, and (3) into the breast pocket after dissection. In addition, ketorolac 30 mg IV and 30 mg IM were given at the end of procedure.
pathways. This method of postsurgical pain control is preferred to singular methods. 18, [34] [35] [36] Numerous studies have shown that a multimodal regimen incorporating several different mechanisms of action has clear advantages over one that employs a single medication. 37 In our study, we looked at 4 different pain regimens: group B, group BL, group BLKi, and group BLKp. Our study shows that intraoperative ketorolac with liposomal bupivacaine and bupivacaine (BLKi) performed the best in terms of lowering narcotic usage and pain scores upon discharge (Fig. 5) .
Additionally, bupivacaine is much more cost-effective, because liposomal bupivacaine costs one hundred times more than standard bupivacaine. 38 As discussed above, avoiding peripheral and central sensitization is an optimal method to decrease post-injury pain. Preventive analgesia utilizes this theory by using analgesia before the painful stimulus to decrease the intensity of the pain. 39 This has been demonstrated in animal studies with substantial results. 5 Because of NSAIDs demonstrating antinociceptive effects both on peripheral and central neurons, ketorolac is an optimal drug for use in preventive analgesia. Local anesthetic can be combined for additional local, peripheral nociceptor blockade to attenuate sensitization before the surgical stimulus. 6, 40 Based on the underlying principal of preemptive analgesia, ketorolac as well as local anesthetic should be given before incision for optimal pain prevention. Ketorolac should be given as preventive analgesia after primary hemostasis has been achieved.
Our study supports that the timing of ketorolac administration greatly influences outcomes. With regards to discharge pain scores and postoperative narcotic usage, our results suggest that intravenous ketorolac given systemically after surgery is less effective than ketorolac given intraoperatively, near the end of surgery. This is supported by a study in hand surgery. Here, preincisional use of both local anesthetics and NSAIDs as opposed to postincisional or postsurgical was superior for adequate pain control. 41, 42 Nonsteroidal anti-inflammatory drugs are still thought to be relatively contraindicated when used preincisionally because of the effect on platelet function, which is crucial for surgical hemostasis. 13 Overall, it is accepted for use preincisionally in small procedures but is still unclear in larger more invasive procedures because of lack of sufficient evidence in its safety. 16, 43 In the neurosurgical population, it is has been associated with higher risk for postoperative hematoma. 44 Others have reported significant blood loss intraoperatively if ketorolac was given before "primary" hemostasis was achieved. 45, 46 There is currently no evidence to suggest any bleeding complications from use of ketorolac after hemostasis was achieved. 47 It is commonly given near the end of surgery. 13 In our study, ketorolac was used postincisional in breast augmentation with no bleeding complications. In both clinical and laboratory studies, bleeding has been demonstrated because of a reversible inhibition of platelet aggregation causing prolonged bleeding times. 30, 48 This, however, does not conclude that ketorolac is unsafe for use. In patients who are not otherwise coagulopathic, it has even been demonstrated as safe with respect to bleeding in surgery patients including those undergoing spinal procedure. 13, [49] [50] [51] [52] There is also a concern among the surgical community that ketorolac can cause acute kidney injury postoperatively. This is a rare event and occurs in approximately 1 in 1000 to 100,000. 53 Its use does not significantly elevate serum creatinine levels and can be used safely. 23, 54 Some studies have shown that the transient fall in postoperative glomerular filtration rate and, thus, renal function is insignificant enough to warrant its use preoperatively. 55 B group, bupivacaine only; BL group, bupivacaine and liposomal bupivacaine; BLKi group, ketorolac given intraoperatively plus bupivacaine and liposomal bupivacaine; BLKp group, ketorolac given postoperatively plus bupivacaine and liposomal bupivacaine. Variables listed above include age; BMI; time PACU, time spent in the PACU; pain po, pain score immediately upon PACU arrival; pain dc, pain score upon discharge; time meds, timing of narcotic administration; amount of meperidine given (mg); patients receiving meperidine; and patients receiving antiemetics.
Studies have found that parenteral ketorolac is associated with upper gastrointestinal adverse events including gastritis, duodenitis, peptic ulcers, and hemorrhage compared with nonuse. 56 Ketorolac should be avoided in patients with malignancy and coagulopathies, as well as chronic kidney disease.
This study found no significant difference in postoperative nausea, vomiting, renal injury, or hemorrhage between these 4 groups.
CONCLUSIONS
Intraoperative ketorolac should be considered as part of the analgesic regimen for acute postoperative pain control in breast augmentation. Its inclusion was significant in decreasing patient use of narcotics and pain upon discharge. Other points to consider include issues of cost, overall patient satisfaction, and safety as compared to narcotics. Addition of other costly drugs such as liposomal bupivacaine may not provide further benefit in the immediate postoperative setting for procedures with a short recovery period such as breast augmentation. Studies have found that compared with narcotics, intravenous ketorolac produced a lower overall mean cost per patient, as well as a higher average patient satisfaction score.
